Leprosy Mailing List Blog: May 2025

Friday, May 30, 2025

Fw: Ref.: (LML) Declaring Leprosy as a Notifiable disease

Leprosy Mailing List – May 30, 2025

Ref.: (LML) Declaring Leprosy as a Notifiable disease

From: Claudio Salgado, Marituba, Brazil

Dear colleagues,

I would like to share some reflections on the importance of making leprosy a compulsory notifiable disease and the implications this could have in our fight against the disease.

First, it is very important that leprosy becomes a notifiable disease across India. In fact, I only recently learned about this and was quite impressed. I had the impression that mandatory notification of leprosy was already a common practice in most countries, as it is in Brazil, where it has been mandatory for decades. Does the mandatory notification in Brazil contribute to our being in second place in the world in terms of case numbers? And will the mandatory notification in India lead to a significant increase in new cases? These questions deserve careful consideration.

Regarding the elimination of leprosy in Jordan, or in other countries, corroborated by the World Health Organization, I have some questions that perhaps cannot be fully answered here, but I believe are important. Besides the more refined clinical semiology now used for the detection of new cases—such as active case finding within families and communities by hansenologists—sensitive laboratory tools like the anti-PGL-I IgM serology, the RLEP quantitative Polymerase Chain Reaction (qPCR RLEP), and complementary examinations such as ultrasonography of peripheral nerves should be part of the investigation routine. I imagine that, in countries that claimed elimination, clinical examinations on the field by hansenologists, laboratory tests, and ultrasonography were rarely used or even neglected, which could explain the discrepancy between epidemiological data and the reality on the ground.

We need to remember that several countries that were considered to have eliminated leprosy as a public health problem, even without the use of these tools, are now facing a significant increase in new cases. Furthermore, the World Health Organization has been promoting a tool to declare the interruption of transmission of Mycobacterium leprae, twenty-five years after the declaration of "elimination" of leprosy as a public health problem, which is based solely on the review of notified epidemiological data, as recently done in the state of Alagoas (Lima LV, Pavinati G, Silva RGTD, et al. Leprosy elimination phase in Alagoas, 2001-2022: an ecological study. Epidemiol Serv Saude. 2025;34:e20240255. Published 2025 Apr 11. doi:10.1590/S2237-96222024v34e20240255.en). In the case of Alagoas, we would very much like the results to be consistent with the reality on the ground, but local colleagues report that the situation does not match in many places. The main reason for this? The global elimination of leprosy diagnosis, which warrants a broader and more in-depth discussion, especially in this forum we have here. How many cases, for example, of fibromyalgia or rheumatoid arthritis with intense pain could actually be leprosy? Or even just pain, with no diagnosis? How many cases of feet with sensory alterations, labeled as diabetes, could in fact be leprosy?

In Brazil, the training of new leprosy specialists has been virtually nonexistent for over forty years. The recent training of new specialists in the state of Mato Grosso by the Brazilian Hansen's Disease Society (SBH) together with the Mato Grosso School of Public Health (ESP-MT) has significantly increased the number of cases detected, making it the state with the highest detection rate in the country. This happens in all places where leprosy specialists are working.

Beyond mandatory notification, in which countries do we have specialists working in the diagnosis of patients not only in reference centers, waiting for patients, but actively in the field—going to homes, schools, prisons, and places where people gather? At some point, someone wrote that diagnosing leprosy was easy. It is not. And we have to face this now. We all know that poor data leads to poor conclusions; in places with diagnostic difficulties, it is impossible to draw reliable conclusions about elimination or the interruption of transmission, whatever that may mean.

Regards,

Claudio

====================================================

Claudio Guedes Salgado, MD, PhD

Full Professor

Institute of Biological Sciences
Pará Federal University

Former President of Brazil Hansen's Disease Society (SBH), 2018-2023

International relations advisor for the SBH

Dermato-Immunology Lab

Av. João Paulo II, 113
Bairro: Dom Aristides
Marituba - Pará - Brasil
CEP: 67200-000
Phone: +55-91-3201-7033

Cell phone: +55-91-991465641
E-mails: csalgado@ufpa.br and claudioguedessalgado@gmail.com

Lattes CV (Brazil format): http://lattes.cnpq.br/2310734509396125

ORCID ID: https://orcid.org/0000-0003-3961-7764

LinkedIn: https://www.linkedin.com/in/claudio-guedes-salgado/
Instagram: https://www.instagram.com/claudiosalgado/

Facebook: https://www.facebook.com/claudioguedessalgado

Map to the Lab: https://goo.gl/maps/7omyd54wy7z

===================================================

________________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/c3752c64-4d87-4c30-8880-829d5009ee8en%40googlegroups.com.

Fw: Ref.: (LML) "What determines a successful leprosy control program: preventing disability and relieving human suffering or Zero leprosy?"

Leprosy Mailing List – May 30, 2025

Ref.: (LML) "What determines a successful leprosy control program: preventing disability and relieving human suffering or Zero leprosy?"

From: Linda Lehman and Pieter Schreuder, USA and the Netherlands

Dear colleagues,

Most of you must have read the report by Wim Theuvenet (LML, May 6, 2025) about Reconstructive surgery, physiotherapy and courses in leprosy and Prevention of Disability (POD), Sulewesi and Ambon, November 2024. Most of you will have concluded that this has been a very important and commendable work. However, this is not a reality for many leprosy patients in many different regions of the world. Not only do only a minority of persons affected by leprosy have access to rehabilitation services (e.g. physiotherapy, occupational therapy, assistive technology and surgery), but many persons are still only diagnosed and treated late after unnecessary delays caused by both patients and health care workers.

In many health services, up to date knowledge of leprosy and especially of POD, is not available. There is an absence of leprosy training courses or refresher courses, irregular and limited supervision, absence of integrated rehabilitation services within all levels of health care and difficulties in referring patients to higher levels of health care. Of course, there are excellent leprosy control programs with dedicated leprosy workers. These programs combine early disease diagnosis with early detection and management of reactions and nerve function impairment. However, reality shows us that many patients still do not receive the timely attention and adequate interventions they need. As a result, there is unnecessary suffering and disability along with continued discrimination and stigma.

Leprosy is not only a medical issue; leprosy requires a multi-disciplinary approach which is patient and family centered. Prevention and management of disabilities requires all disciplines to work together, and rehabilitation interventions to be integrated within community, primary, secondary and tertiary health care to get optimal results assuring mental well-being, function and participation.

The critical area still causing suffering and disability is the inadequate detection and management of reactions and neuritis at diagnosis, during MDT and after completion of MDT. The diagnosis, treatment and follow-up of neuritis can only be successful when medical treatment includes and integrates POD and timely surgical Rehabilitation intervention.

The ultimate goal of leprosy control programs is to reach Zero Leprosy. However, true success requires us to also include and measure our ability to alleviate human suffering, discrimination and disability. Let the Conference in Bali have no illusions about Zero Leprosy success if it has not addressed and measured success of a bigger goal that successfully manages disease, disability and discrimination.

Regards,

Linda Lehman

Pieter Schreuder

________________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/20ae51b5-675a-419c-8908-e74ff658c60en%40googlegroups.com.

Thursday, May 29, 2025

Fw: Ref.: (LML) Mapping seminar at ILC

Leprosy Mailing List – May 29, 2025

Ref.: (LML) Mapping seminar at ILC

From: Epco Hasker, Antwerp, Belgium

Dear Pieter,

We are planning a seminar on mapping for leprosy program and NGO staff, on 10 July in Bali, the day after the ILC. Attendance will be free for those interested. Attached is a preliminary program, to be finalized asap. Is this something we could circulate via the LML?

Best regards,

Epco

Epco Hasker MD, PhD

Mycobacterial Diseases and Neglected Tropical Diseases

Tel: +32(0)32470726

ehasker@itg.be / www.itg.be

________________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/88cb2e5d-e833-4798-bd4d-af308c78fd7en%40googlegroups.com.

Fw: Ref.: (LML) Declaring Leprosy as a Notifiable disease across India

Leprosy Mailing List – May 29, 2025

Ref.: (LML) Declaring Leprosy as a Notifiable disease across India

From: Joseph N. Chukwu, Enugu, Nigeria.

'Yes, leprosy was a notifiable disease in Jordan before the World Health Organisation (WHO) verified its elimination last year, In fact Jordan has not reported any new, locally acquired (autochthonous) cases of leprosy for over two decades. The WHO's verification of leprosy elimination in Jordan signifies the end of a period where leprosy was a notifiable disease in the country.

Dear Pieter,

The above statement was Google's response to my query: 'was leprosy a notifiable disease in Jordan before WHO verified that Jordan had eliminated leprosy last year'.

The backdrop to all this was of course your recent publication in LML of a communication by our distinguished colleague Prof. P. Narasimha (President of the International Leprosy Association) of the important news that the government of India has declared leprosy a notifiable disease nationwide (Ref: LML May 24, 2025 – Declaring Leprosy as a notifiable disease across India).

According to the communication, this order states, among other things, that 'reporting of all diagnosed cases of leprosy to the district leprosy officer or Chief Medical Officer of the respective district should be mandatory'. It goes on, 'in order to achieve the objective of leprosy-free status in a region, it is imperative that every new detected case of leprosy is reported promptly.'

I write to applaud the government of India for this intervention. The timing could not have been more auspicious, coming less than two months before the upcoming 22^nd. International leprosy Congress in Bali, Indonesia.

I urge all leprosy-endemic countries, especially those targeting elimination of the disease, to follow the Indian example without delay.

If conscientiously implemented, the intervention has the potential to contribute to heightened awareness especially among private-sector clinicians, as well as improved case notification and surveillance.

The urgent need to make leprosy a notifiable disease in leprosy-endemic countries should be one of the take-home messages of the upcoming 22^nd. International Leprosy Congress in Bali.

The leaderships of the International Leprosy Association (ILA) and the International Federation of anti-leprosy associations (ILEP) should use their well-established global networks to lead the advocacy needed to promote the cause.

Thank you very much Pieter, for the good work you and your team continue to do on behalf of all of us.

Joseph N. Chukwu

Enugu, Nigeria.

________________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/d40e46cd-727a-4f29-b727-bba189c3f84an%40googlegroups.com.

Saturday, May 24, 2025

Fw: Ref.: (LML) Declaring Leprosy as a Notifiable disease across India

Leprosy Mailing List – May 24, 2025

Ref.: (LML) Declaring Leprosy as a Notifiable disease across India

From: P. Narasimha Rao, Hyderabad, India

Dear Pieter,

India is a large country with 28 states and 8 union territories (UT) and Government of India is making concerted efforts to eliminate leprosy. However, Leprosy was not a notifiable disease across India till now, although it is a notifiable disease in States like Tamil Nadu, Odisha, and Karnataka. At this juncture it is relevant to note that administration of 'Health' is a state subject matter in India, although the national health policies are recommended/ promulgated by the Ministry of Health (MoH), Govt of India.

I am happy to share the news that the Govt of India has taken the decision to make 'Leprosy a notifiable disease' across India and announced the same through a DO letter, (D.O. No. Z-14020/05/2025-Lep. from MOHFW, Govt of India, dated 14 May, 2025), signed by the Secretary, MOH, Govt of India. Through this letter, the Secretary, MOH, Govt of India has directed all its state and UT health administration to declare leprosy as a 'Notifiable Disease', applicable across all sectors—government, private, non-governmental organizations (NGOs), corporate health-care-providers, and medical institutions, including private medical colleges.

This letter states that reporting of all diagnosed cases of leprosy to the District Leprosy Officer or Chief Medical Officer of the respective district should be mandatory. It also mentions that in order to achieve the objective of leprosy-free status in a region, it is imperative that every newly detected case of leprosy is reported promptly. a) to the National Leprosy Eradication Program (NLEP) to ensure that all patients benefit from the services available under NLEP and b) to facilitate the administration of chemoprophylaxis to healthy contacts to prevent further transmission.

All the major stakeholders of Indian leprosy, including the (IAL (The Indian Association of Leprologists) and IADVL have welcomed this decision, as non-notification of leprosy was an impediment in collecting factual leprosy data across India till now.

Kind regards,

P. Narasimha Rao, MD, D.D, PhD

President, International Leprosy Association (ILA)

Immediate Past President, Indian Association of Leprologists (IAL)

Past President, Indian Association of Dermatologists, Venereologists and Leprologists (IADVL)

Mobile-+91-9849044898

Email: <dermarao@gmail.com>, <int.lepr.association@gmail.com>

Website: www.internationalleprosyassociation.org

_______________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/b520f53a-7788-4c1c-b7cd-959451dc1df1n%40googlegroups.com.

Monday, May 12, 2025

Fw: Ref.: (LML) Infolep monthly overview of new publications on leprosy. May 2025.

Leprosy Mailing List – May 13, 2025

Ref.: (LML) Infolep monthly overview of new publications on leprosy. May 2025.

From: Lukas Maass & Roos Geutjes, Amsterdam, the Netherlands

Dear colleagues,

We spotlight the upcoming launch of the ILEP Ocular Leprosy Photo Database—a collaborative effort to enhance early detection and training. Your support is greatly appreciated!

We're excited to introduce Lukas Maass, who has recently joined as Support Officer for Infolep and InfoNTD. With a background in global health and a strong interest in knowledge sharing, Lukas will support the platforms' development and user engagement.

Enjoy reading the latest publications that are listed below. Feel free to contact us to receive the full-text versions when these cannot be found on Infolep. We would also be happy to assist you with literature searches.

Warm regards,

Lukas Maass & Roos Geutjes

www.leprosy-information.org
info@infolep.org

ILEP Ocular Leprosy Database

Ocular leprosy complications can cause irreversible disability and lead to blindness. They are often unrecognized and unreported.

Significant challenges include gaps in understanding the extent of leprosy-related blindness, and lack of a global repository of ocular leprosy photographs to train frontline health workers. Both will impact timely detection and intervention, which are crucial to prevent blindness.

The ILEP ocular leprosy photo database addresses these challenges by leveraging the potential of digital technology. The database will be launched in July 2025 and hosted on Infolep.

We are inviting ophthalmologists, field workers and all health professionals to submit ocular leprosy photographs and relevant patient metadata on an ongoing basis, to help build this vital database.

Your contributions will be instrumental to populating the database, and advancing integrated service delivery, training, research, and AI-based screening tools for ocular leprosy.

The necessary instructions are included on this guidance document. Many thanks in advance for your support!

Practical resources

Six guiding principles to support equity in global health programmes
Knowledge for Development and Diplomacy. 2025.

DHIS2-based leprosy/Hansen disease Elimination Monitoring Tool (LEMT) – Standard operating procedures
WHO Regional Office South-East Asia. 2025.

Global Antimicrobial Resistance and Use Surveillance System (GLASS) report Antibiotic use data for 2022
World Health Organization. 2025.

New publications

Feel free to contact us to receive full-text versions if these cannot be found through the Infolep portal.

Acceptability and feasibility of chemoprophylaxis with single-dose rifampicin in four leprosy-endemic districts in Benin
Djossou P, Mignanwande ZFM, Anagonou SGE, et al. Public Library of Science (PLoS). PLOS Neglected Tropical Diseases. 2025; 19 (4) : e0013057.

Global Trends in the Incidence, Prevalence and Disability-Adjusted Life Years of Leprosy from 1990 to 2019: An Age-Period-Cohort Analysis Using the Global Burden of Disease Study 2019
Ke Zhang, Wei Zhang, Hongguang Lu. Clinical, Cosmetic and Investigational Dermatology. Informa UK Limited 2025;

Global trends and burdens of neglected tropical diseases and malaria from 1990 to 2021: a systematic analysis of the Global Burden of Disease Study 2021
Chen J, Tian X, Guo D, et al. Springer Science and Business Media LLC. BMC Public Health. 2025.

Representaciones sociales de la lepra en médicos de urgencias en Cali, Colombia
Ordóñez-Hernández CA, Guzmán-Mendoza OE, Lozano G, et al. Elsevier BV. Piel. 2025.

Digital Health Tools and Their Application in Disability Support
Chavhan GH. Modern Digital Approaches to Care Technologies for Individuals With Disabilities. IGI Global. 2025.

Empowering Individuals With Disabilities: The Role of Mobile Health Apps in Enhancing Accessibility and Health Outcomes
Ingle AW, Kshirsagar KP, Gawande PG. IGI Global. Modern Digital Approaches to Care Technologies for Individuals With Disabilities. 2025.

Self-Acceptance Among Leprosy Patients: A Qualitative Exploration of Personal and Social Challenges
Rinto Baro Kaleka V, Damayanti Y, Christine Pello S. Journal of Health and Behavioral Science. 2025.

Fisioterapia na Qualidade de Vida de Pacientes com Hanseníase
Barbosa FHS, Macêdo GS, Oliveira MRDSD. REVISTA FOCO. Brazilian Journals. 2025; 18 (5) : 1-9.

Challenges and opportunities in the development and implementation of zero leprosy roadmaps in low-endemic settings: Experiences from Bolivia, Pakistan, and Togo
Fastenau A, Schwermann F, Mora AB, et al. Public Library of Science (PLoS). PLOS Neglected Tropical Diseases. 2025; 19 (4) : e0013009.

Leprosy with comorbidities: A call for strengthening vigilance
Ramasamy S, Panneerselvam S, Agrawal S. Ovid Technologies (Wolters Kluwer Health). Journal of Family Medicine and Primary Care. 2025; 14 (4) : 1572-1573.

Ensino da hanseníase nas faculdades de medicina de um estado com baixa endemicidade
Vitiritti Ferreira Zanardo B, Baruffi PP, Ens RT. Universidade Estadual do Parana - Unespar. Ensino & Pesquisa. 2025; 23 (1) : 712-723.

A importancia da atuaçao farmaceutica na abordagem multidisciplinar de pacientes com Hanseníase
GAMA SIQUEIRA G, SARAIVA DE ANDRADE RODRIGUES R. Guilherme Barroso L. De Freitas. Imunologia e Doenças Infecciosas e Parasitárias - Edição III. 2025.

Leprosy elimination phase in Alagoas, 2001-2022: an ecological study
Lima LVD, Pavinati G, Silva RGTD, et al. FapUNIFESP (SciELO). Epidemiologia e Serviços de Saúde. 2025.

Incidence and Clinical Patterns of Leprosy in Interior Sindh; Retrospective Study
Jaikishan , Gemnani V, Abro K, et al. Med Forum. 2025; 36 (1) : 6.

Unprecedented in vivo activity of telacebec against Mycobacterium leprae
Chauffour A, Cambau E, Pethe K, et al. Public Library of Science (PLoS). PLOS Neglected Tropical Diseases. 2025; 19 (5) : e0013076.

The Effectiveness of Compassion-Focused Therapy on Psychological Distress Individuals with Leprosy in Tabriz
Elbeigy Zanganeh I, Kazemi AS, Rasouli N. The Effectiveness of Compassion-Focused Therapy on Psychological Distress Individuals with Leprosy in Tabriz. Int J Body Mind Cult. 12(2):74–80.

High Serum Levels of Transforming Growth Factor β1 (TGF-β1) a Risk Factor for Neuropathic Pain in Patients with Multibacillary Leprosy
Suari, D. A. N., Widyadharma, I. P. E., Utami, D. K. I. (2025). High Serum Levels of Transforming Growth Factor β1 (TGF-β1) a Risk Factor for Neuropathic Pain in Patients with Multibacillary Leprosy. International Journal of Scientific Advances (IJSCIA), Volume 6| Issue 3: May-Jun 2025, Pages 406-411.

Data-Based Evidence on the Causality Model of Social Stigma on Medication Compliance in Leprosy Patients in Bone District, Indonesia
Haerana BT, Mariani , Sadarang RAI, et al. Window of Health : Jurnal Kesehatan. Universitas Muslim Indonesia. 2025; 8 (2) : 145-156.

What matters most in Cirebon, Indonesia: cultural nuances to health-related stigma
Sopamena Y, Sutiawan R, Visser MJ, et al. Global Public Health. Informa UK Limited. 2025.

Audiological findings in patients with leprosy
Uzut M, Erdur Uzut S, Kayhan FT, et al. Informa UK Limited. Acta Oto-Laryngologica. 2025; 145 (5) : 395-399.

Comments on "Cranial nerve palsies in leprosy: a systematic review of published case reports and case series"
Namdar AB, Keikha M. Springer Science and Business Media LLC. Acta Neurologica Belgica. 2025.

Leprosy: health education with children and adolescents – systematic review / Hanseníase: educação em saúde com crianças e adolescentes – revisão sistemática
Francisco MM, Albuquerque MIND, Santos LMDS, et al. Universidade Federal do Estado do Rio de Janeiro UNIRIO. Revista de Pesquisa Cuidado é Fundamental Online. 2025.

Distribuição espacial e perfis epidemiológicos da hanseníase em Anápolis (GO): um estudo de 2019-2024
Castro IDOE, Castro LC, Chaul SFM, et al. Revista Eletrônica Acervo Saúde. Revista Eletronica Acervo Saude. 2025.

The successful implementation of comprehensive control paradigm for eliminating leprosy in Yunnan Province, China
Ma T, Zhen Q, Guo F, et al. Journal of Infection. Elsevier BV. 2025; 90 (6) : 1-7.

Time Series Analysis For Leprosy in Tocantins
Ferreira KCCL, Santos AJFD, Gomes H, et al. Revista de Gestão Social e Ambiental. RGSA- Revista de Gestao Social e Ambiental. 2025; 19 (4) : 1-15.

Penyimpanan informasi rekam medis kesehatan dalam bentuk program pencegahan dan penanganan kusta di Indonesia
Trisnanto PY, Gunawan . JURNAL TEKNOLOGI KONSEPTUAL DESAIN. 2025.

Increased <CD8dim and Decreased CD8brigh T Cells as Immunological Signature for Multibacilary Leprosy Patients
de Castro YS, Nascimento LS, da Silva JA, et al. Wiley. Immunology. 2025.

Case Reports

Unmasking the mimic: Leprosy neuropathy misdiagnosed as chronic inflammatory demyelinating polyneuropathy: A case report from Saudi Arabia
AlOtaibi MK, AlQahtani BG, AlQawahmed RM. Saudi Medical Journal. Neurosciences. 2025; 30 (2) : 5.

News & Events

Mentorship Opportunity: Empower Women in NTD Leadership
The Mwele Malecela Mentorship (MMM) Program for Women in NTDs aims to increase gender equality in representation and leadership by developing and supporting mid-career African women to become leaders and champions in NTD elimination at national and international levels. The application period closes on May 12, 2025.

WHO Director General's opening remarks at the Member State briefing on the programme budget– 22 April 2025
News item by the World Health Organization.

African health experts commit to accelerate efforts to eliminate Neglected Tropical Diseases | InfoNTD
Lomé – African health experts have renewed commitment to accelerate efforts to end Neglected Tropical Diseases (NTDs) that continue to affect over a billion people globally, 40% of whom live in the African region.

16th Annual NNN Conference 2025
September 30-October 2, 2025; Kampala, Uganda
The conference will see NTD practitioners, government officials, community leaders, researchers, policymakers, and other stakeholders from over 50 countries deliberating on challenges and solutions for NTD elimination. Submissions for the 2025 conference will open in April 2025.

World Health Summit 2025
October 12-14, 2025; Berlin, Germany & Online
The World Health Summit is the unique international strategic forum for global health. Held annually in Berlin, it brings together stakeholders from politics, science, the private sector, and civil society from around the world to set the agenda for a healthier future by inspiring innovative solutions for better health and well-being for all.

3rd Global Forum of People's Organizations on Hansen's Diseas
July 4-6, 2025; Bali, Indonesia
ILEP member Sasakawa Health Foundation, in consultation with persons affected by leprosy and other stakeholders, is organizing the 3^rd Global Forum of People's Organizations.

22nd International Leprosy Congress
July 5-9, 2025; Bali Nusa Dua Convention Centra (BNDCC), Bali, Indonesia
This year the 22nd International Leprosy Congress (ILC) will be held in Bali, Indonesia! The congress uphold the theme: "Towards a World with Zero Leprosy". The theme aims to enhance the evidence into the clinical care in leprosy early diagnosis and therapeutics in the global era and prepare to face the new perspective of dermatology practice. The deadline for late registration is July the 6th.

European Congress for Tropical Medicine and International Health 2025
September 29-October 2, 2025, Hamburg
Save the Date! ECTMIH 2025 is currently still in the planning stage. All information is expected to be available from January 2025 and registration will be possible from then on.

WHA78 Side Event "Health Financing: What now? What next? Insights from malaria, dengue & Neglected Tropical Diseases
Hotel Royal, Geneva, Switzerland

Call for applications: 2025 RSTMH Early Career Grants Programme
The Royal Society of Tropical Medicine and Hygiene. The projects can be on any topic related to tropical medicine and global health, from across the research spectrum of lab, translation, implementation, and policy. Apply for an RSTMH Early Career Grant by 12:00 PM BST (midday) on Wednesday 14 May 2025.

Links

Info Hansen - A innovative hub for knowledge sharing about Hansen's Disease

ALLF - Official website of the Association des Léprologues de Langue Française

LML - Leprosy Mailing List - a free moderated email list that allows all persons interested in leprosy to share ideas, information, experiences and questions

InfoNTD - Information on cross-cutting issues in Neglected Tropical Diseases (NTDs)

ILEP newsletter archive

GPZL newsletter subscription

WHO Goodwill Ambassador's Leprosy Bulletin

Leprosy Review

Leprosy Review Repository (1928-2001)

Fontilles Revista de Leprología

Indian Journal of Leprosy

Hansenologia Internationalis

HARP - Hansen's Disease Antimicrobial Resistance Profiles

GDPR & the Infolep newsletter

New EU data protection regulations came into force on 25 May 2018. We have been reviewing our practices with regards to the GDPR, including our privacy statement and mailing list.

Infolep sends out monthly e-mails with an overview of recent publications on leprosy and related issues. The purpose of this activity is to keep subscribers up to date.

Infolep will only process the data we have (names, email addresses) for the purpose of sending you the newsletter. We take your security seriously and will never share your contact details with anyone else.

You can update your preferences or unsubscribe from this list at any time.

Send us an email

Visit our website

Facebook

________________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/c41fb1ca-86a0-4605-8fd2-579e4782d656n%40googlegroups.com.